The compound of formula (I) has a good inhibitory effect on the proliferation of human prostate cancer cells CWR22RV1 and breast cancer cells; and combined use of the compound with an androgen receptor inhibitor HC-1119 significantly enhances the inhibitory effect on prostate cancer cells, and the inhibitory effect increases with increased concentration. The compound of formula (I) can not only be used independently to prepare an antineoplastic agent but can also be used in combination with other agents having antineoplastic effects, such as an androgen receptor inhibitor, or other targeting drugs etc., to prepare an antineoplastic agent having stronger therapeutic effects, especially an agent for treating prostate cancer and breast cancer.
公式(I)的化合物对人前列腺癌细胞CW
R22RV1和乳腺癌细胞的增殖具有良好的抑制作用;该化合物与雄激素受体
抑制剂HC-1119的联合使用显著增强了对前列腺癌细胞的抑制作用,并且随着浓度的增加,抑制作用也增加。公式(I)的化合物不仅可以独立使用以制备
抗肿瘤药剂,还可以与其他具有抗肿瘤效果的药剂结合使用,如雄激素受体
抑制剂或其他靶向药物等,以制备具有更强治疗效果的
抗肿瘤药剂,特别是用于治疗前列腺癌和乳腺癌的药剂。